Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate ‘Bersiporocin’ at ERS 2026

104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion